Results according to the studies on hyperthermia

Several retrospective clinical studies are available to indicate the hyperthermia effects on patients (1)(2). Hyperthermia is commonly used for complex and very frequent tumors like lung, liver, pancreas, brain, gastrointestinal, gynecological, etc. cancers. We at the Hyperthermia Centre Hannover use Oncotherm hyperthermia machines in our hyperthermia therapies.
Oncotherm notes, that it has not performed – until now – prospective evidence based clinical trial with oncothermia machines (3).

The main reasons are:
it is applied mostly for far advanced cancer cases, where evidence based medicine has no effect anymore. Please note, that in this category evidence based trials do not exist in this treatment line for pharmaceutical products too.
evidence based studies are too expensive compared to the facilities of the company.
and most users (doctors, medical center’s) run a private clinic, having no interest to make such studies.

It is noted, however, that retrospective studies and case reports on huge number’s of patients show amazingly good results in all the registered localizations. The best enhancements are in the brain-gliomas (n=, %). The retrospective analyses in independent clinics show coherence in the success, and definitely and significantly higher survival time than the large databases (SEER [4], Eurocare [5]).
Hyperthermia is applied when other treatment options fail. Thus patients with long survival rates could have not observable life-elongation, even if a hyperthermia therapy was effective. Oncotherm states, that “a aggressive disease with short survival is a chance to indicate the efficacy. For these reasons we compare the 1st year survivals rate only (see Fig 1.). In this sense oncothermia is indicated as a feasible, effective method [6]; [7], [8], [9].”

REFERENCES
[1] Dani A, Varkonyi A, Magyar T, Szasz A (2009) A retrospective study of 1180 cancer patients treated by oncothermia. Forum Hyperthermia in print (pp. 1-11).
[2] Szasz A (2009) Clinical studies evidences of modulated rf-conductive heating (mEHT) method. Paper presented at the 25th Annual Meeting of the European Society for Hyperthermic Oncology, ESHO, Verona, Italy, 4-6 June 2009
[3] https://www.oncotherm.de/web/cus/(00)%20Oncothermia%20summary.pdf, page 10
[4] Surveillance, Epidemiology, and End Results (SEER), National Cancer Institute. www.seer.cancer.gov. April, 2000
[5] EUROCARE-3, European Cancer Database. www.eurocare.org/profiles/index.html
[6] Szasz A et al (2005) Retrospective analysis of 1180 oncological patients treated by electro-hyperthermia in Hungary.
Jahreskongress der Deutschen Gesellschaft für Radioonkologie, DEGRO 11, Karlsruhe, 26-29 May 2005[7] Sahinbas H, Grönemeyer D (2002) Local and regional deep-hyperthermia in combination with radiation- and chemotherapy for
advanced tumors. 20th European Society for hyperthermic oncology, Bergen, Norway, 23-25 May 2002[8] Kleef R et al (2004) Locoregional hyperthermia in advanced cancer – case reports and research perspectives. ICHS Conference,Shenzhen, China
[9] Szasz A, Dani A, Varkonyi A (2004) Az elektro-hipertermia eredményei nagyszámú beteg retrospektív kiértékelésének tükrében
Magyarországon. Magyar Klinikai Onkológiai Társaság III. Kongresszusa, Budapest, Hungary, 17-20 November 2004
Official studies on hyperthermia
Today, a growing number of university experts in cancer therapy also see the necessity for personalised and individual treatment with medication and food supplements.
Below you find a brief list of Publications in relation with hyperthermia:
Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
Oct 2012 – Br J Anaesth; 109(5):1471-6771 [PMID:22855633]
[Sulyok I] [Fleischmann E] [Stift A] [Roth G] [Lebherz-Eichinger D] [Kasper D] [Spittler A][Kimberger O]
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone.Sep 2012 – Int J Hyperthermia:1464-5157 [PMID:23006132]
[Schroeder C] [Gani C] [Lamprecht U] [Hann von Weyhern C] [Weinmann M] [Bamberg M] [Berger B]Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia.
Jul 2012 – :1532-2807 [PMID:22752712]
[Rubovszky G] [Nagy T] [Godény M] [Szász A] [Láng I]
Old and new facts about hyperthermia-induced modulations of the immune system.
Jun 2012 – :1464-5157 [PMID:22690925]
[Frey B] [Weiss EM] [Rubner Y] [Wunderlich R] [Ott OJ] [Sauer R] [Fietkau R] [Gaipl US]
Effector CD8(+ )T cell IFN-? production and cytotoxicity are enhanced by mild hyperthermia.
Jan 2012 – Int J Hyperthermia; 28(1):1464-5157 [PMID:22235780]
[Mace TA] [Zhong L] [Kokolus KM] [Repasky EA]